SAN CARLOS, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Nektar Therapeutics announced that it will host an R&D Day for investors and analysts at the InterContinental Hotel in New York on Wednesday, November 12, 2008, beginning at 12:00 p.m. Eastern Time. The webcast portion of this event will conclude at approximately 3:30 p.m.
Nektar's R&D Day will consist of a series of presentations and Q&A related to the Company's clinical development programs, key research and development, and industry-leading PEGylation and conjugate chemistry-based drug development platform.
The presentations and Q&A sessions will be accessible via a live audio and slideshow webcast through a link on the Nektar homepage, http://www.nektar.com. The webcast will be available for replay until November 26, 2008.
About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and conjugate chemistry technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.
CONTACT: Stephan Herrera, +1-415-488-7699, sherrera@nektar.com, or
Jennifer Ruddock, +1-650-631-4954, jruddock@nektar.com, both of Nektar
Therapeutics
Web site: http://www.nektar.com/
